TEM
Tempus AI, Inc. Class A Common Stock
About: Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Employees: 2,400
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
286% more first-time investments, than exits
New positions opened: 81 | Existing positions closed: 21
214% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 14
62% more call options, than puts
Call options by funds: $75.7M | Put options by funds: $46.8M
61% more funds holding
Funds holding: 96 [Q3] → 155 (+59) [Q4]
17% more funds holding in top 10
Funds holding in top 10: 6 [Q3] → 7 (+1) [Q4]
8.72% more ownership
Funds ownership: 25.2% [Q3] → 33.92% (+8.72%) [Q4]
18% less capital invested
Capital invested by funds: $2.12B [Q3] → $1.75B (-$374M) [Q4]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$55
6%
upside
Avg. target
$62
20%
upside
High target
$74
43%
upside
7 analyst ratings
4 positive
57%
3 neutral
43%
0 negative
0%
Needham Ryan MacDonald 35% 1-year accuracy 28 / 81 met price target | 35%upside $70 | Buy Reiterated | 24 Apr 2025 |
BTIG Mark Massaro 57% 1-year accuracy 13 / 23 met price target | 16%upside $60 | Buy Initiated | 21 Apr 2025 |
Morgan Stanley Tejas Savant 26% 1-year accuracy 5 / 19 met price target | 16%upside $60 | Overweight Maintained | 6 Mar 2025 |
Piper Sandler David Westenberg 45% 1-year accuracy 19 / 42 met price target | 6%upside $55 | Neutral Maintained | 4 Mar 2025 |
B of A Securities Michael Ryskin 60% 1-year accuracy 3 / 5 met price target | 16%upside $60 | Neutral Maintained | 3 Mar 2025 |
Financial journalist opinion
Based on 19 articles about TEM published over the past 30 days
Neutral
Business Wire
1 day ago
Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Analytical Validation of NGS-based Comprehensive Liquid Biopsy Assay for Therapy” in the Journal of Molecular Diagnostics. Data from this study supports the utility of xF+ as a non-invasive technique to detect actionable variants including resistance mutations, identify clinically relevant biomarkers,.
Positive
Zacks Investment Research
2 days ago
Tempus AI Stock Surges 43% in Q1: Buy Now or Wait for Earnings?
TEM's Genomics unit is expected to report strong growth for the first quarter, banking on continued unit growth pick-up.
Neutral
Business Wire
2 days ago
Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced Tempus Loop, a new oncology-focused platform for target discovery and validation. Loop is Tempus' proprietary approach to novel target identification that integrates real-world patient data (RWD) with human-derived biological models and CRISPR-screens, all leveraging AI to rapidly uncover insights for pre-clinical therapeutic de.
Neutral
Business Wire
5 days ago
Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that 18 abstracts, including one oral presentation, have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, on April 25 - 30 in Chicago. Tempus researchers will showcase scientific and clinical research that highlight the transformative impact of AI on oncology treatment an.
Positive
Zacks Investment Research
6 days ago
Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal?
Tempus AI TEM has skyrocketed 21% in the last three days, fueled by news of a $200 million partnership with AstraZeneca AZN and Pathos AI. The multi-year deal focuses on building a multimodal AI-driven foundation model for oncology, using TempusAI's de-identified oncology data.
Neutral
Business Wire
6 days ago
Tempus to Report First Quarter 2025 Financial Results on May 6
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on Tuesday, May 6, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible.
Positive
The Motley Fool
1 week ago
Tempus AI Is Skyrocketing Today -- Is the Stock a Buy Right Now?
Amid a bullish backdrop for the broader market, Tempus AI (TEM 17.72%) stock is posting big gains Wednesday. The company's share price was up 15.8% as of 1:45 p.m.
Positive
24/7 Wall Street
1 week ago
Discover Why Quantum Computing Stocks Are Soaring Today
With the stock market in rally mode, there are more pockets of strength than there have been in a while.
Positive
Proactive Investors
1 week ago
Tempus AI shares jump on new oncology AI partnerships with AstraZeneca, Pathos
Tempus AI (NASDAQ:TEM) said on Wednesday it has signed multi-year strategic collaborations with AstraZeneca (AZN.L) and Pathos AI to co-develop what it called the largest multimodal foundation model in oncology, sending its shares up more than 15% in morning trading. The deals, which include $200 million in data licensing and model development fees to Tempus, will leverage the company's vast repository of de-identified oncology data and artificial intelligence capabilities to help identify new drug targets and advance cancer therapies.
Positive
The Motley Fool
1 week ago
Why Tempus AI Stock Is Skyrocketing Today
Shares of Tempus AI (TEM 17.39%) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday.
Charts implemented using Lightweight Charts™